Allison McGeer

Last updated
Allison McGeer
FRCPC
Born1953 (age 70–71)
Alma mater University of Toronto (BS, MSc, MD)
Known forPandemic response
Scientific career
Institutions Sinai Health System
Dalla Lana School of Public Health
Lunenfeld-Tanenbaum Research Institute
Department of Laboratory Medicine & Pathobiology at the University of Toronto

Allison Joan McGeer (born 1953) is a Canadian infectious disease specialist in the Sinai Health System, and a professor in the Department of Laboratory Medicine and Pathobiology at the University of Toronto. She also appointed at the Dalla Lana School of Public Health and a Senior Clinician Scientist at the Lunenfeld-Tanenbaum Research Institute, and is a partner of the National Collaborating Centre for Infectious Diseases. McGeer has led investigations into the severe acute respiratory syndrome outbreak in Toronto and worked alongside Donald Low. During the COVID-19 pandemic, McGeer has studied how SARS-CoV-2 survives in the air and has served on several provincial committees advising aspects of the Government of Ontario's pandemic response.

Contents

Early life and education

In 1974, McGeer earned a B.Sc. in biochemistry from the University of Toronto. [1] She earned a master's degree and then an M.D. in 1982. [1] [2] She trained in internal medicine and infectious diseases at the University of Toronto. From 1989 to 1990, McGeer was a clinical fellow in hospital epidemiology at Yale New Haven Hospital. [2]

Career

In 1989, McGeer joined the Sinai Health System, where she specialised in microbiology. [2] She holds a joint position as Professor in the Department of Laboratory Medicine and Pathobiology and of Infectious Diseases at the Dalla Lana School of Public Health. [3]

At the University of Toronto, she has focussed on developing mechanisms to stop the spread of infectious diseases in hospitals and care homes. [2] [4] McGeer has studied the impact of influenza on hospital staff. She encouraged people of all ages to receive the universal flu vaccine and supported hospitals in improving their influenza testing. [5] She also contributed to a review of influenza diagnosis among older hospitalized patients on behalf of the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network. [6]

She is the director of infection control, and works as a microbiologist and infectious disease consultant at the Mount Sinai Hospital. Her staff directory page acknowledges funding through an unrestricted educational grant from Pfizer Canada. [2]

McGeer studies the prevention and management of bacterial and viral infections. [7] Her primary areas of research interest are the prevention of healthcare associated infection, the epidemiology of influenza, and adult immunization. She has received research grants from Pfizer and Seqirus, as well as personal and consulting fees from AstraZeneca, GlaxoSmithKline, Janssen, Medicago, Merck, Moderna, and Sanofi Pasteur. [8] [9] [10]

SARS and MERS

McGeer led the investigations into Severe Acute Respiratory Syndrome (SARS) in Toronto. [11] [12] [13] [14] She was based at the Ontario SARS emergency operation centre. At the time, she contracted the disease, [15] and accidentally exposed several other health officials to the disease. [16] The health officials were quarantined and did not develop the disease. The basic reproduction number of severe acute respiratory syndrome-related coronavirus (SARS-CoV) was between 2.2 and 3.7, but super-spreading events (highly efficient transmission of the virus) occurred in some hospital settings. [17] [18] McGeer believes that Toronto eliminated SARS by isolating people who were infected or at risk from the virus, preventing its spread. [19] A study the critical care units of Toronto's hospitals found that the consistent use of N95 masks was an effective way to protect nurses. [17] [20] During the 2013 MERS outbreak, McGeer visited Saudi Arabia with the World Health Organization to help to track the spread of the virus. [21] [22] [23] Through careful monitoring of the air, food and water supply, McGeer helped to control the spread of the virus. [21]

COVID-19 pandemic

Throughout the COVID-19 pandemic McGeer provided health advice to the Canadian public, [24] [25] [26] including as a member of the Ontario COVID-19 Science Advisory Table. [27] She also serves on Canada's COVID-19 Expert Panel, assembled by Chief Science Advisor of Canada Dr. Mona Nemer to assist in providing advice and guidance to Prime Minister Justin Trudeau and the federal government. [28] In late January 2020, McGeer expressed concerns over the ability to contain SARS-CoV-2, [29] [30] particularly the unknown incubation period, which makes it difficult to track and quarantine people who have been exposed. [31] In early March she emphasized the need for Canadians to follow public health advice to prevent the widespread transmission of SARS-CoV-2. [32] According to McGeer, the most important guidance was to limit social contact and stay at home when feeling unwell. [25] [32] [33]

McGeer started to investigate how long SARS-CoV-2 can survive in air in March 2020. [34] She was interested in how exhaled droplets, which contain both water and the virus, may become an infective aerosol that is light enough to be transported by air currents. [34] Caroline Duchaine, an aerosol specialist at the Université Laval, thinks that the virus may not be as potent in aerosol form, losing parts of its spiky protein shell as it dries out in the air. [34] McGeer and Duchaine are interested in how the virus survives in air in a hospital setting, particularly around patients who are being intubated. [34] She hopes her research will provide insight as to whether face masks should be worn to reduce the transmission of the virus. [34] At the time, the Centers for Disease Control and Prevention were considering whether to advise members of the public to wear masks when they left the house, and they had been made mandatory in the Czech Republic. [35]

In her role at Mount Sinai Hospital, McGeer acted as a local principal investigator for the "CONvalescent Plasma for Hospitalized Adults With COVID-19 Respiratory Illness" (CONCOR-1) study. [36] She also served as a principal investigator on a study examining the association between frailty and outcomes of COVID-19 infection. [37]

In May 2021, McGeer explained that National Advisory Committee on Immunization (NACI) deliberations to approve COVID-19 vaccines couldn't be made available to the public because the agency "has nothing like the budget or staff that would be needed" to do so. While NACI is mandated to "gather and evaluate the available data relevant to vaccines," McGeer also noted "they are not adequately resourced for rapid and comprehensive scientific assessment." [38] She welcomed NACI's September 2021 recommendation of a COVID-19 vaccine booster shot for residents of long-term and congregate care facilities, citing evidence of waning immunity among this population. [39]

McGeer was recruited as a member of the newly formed Ontario Immunization Advisory Committee (OIAC), created by Chief Medical Officer of Health Kieran Moore in August 2021 to work on provincial vaccine programs (including for COVID-19). [40]

Membership

Awards

Selected works and publications

See also

Related Research Articles

<span class="mw-page-title-main">SARS</span> Disease caused by severe acute respiratory syndrome coronavirus

Severe acute respiratory syndrome (SARS) is a viral respiratory disease of zoonotic origin caused by the virus SARS-CoV-1, the first identified strain of the SARS-related coronavirus. The first known cases occurred in November 2002, and the syndrome caused the 2002–2004 SARS outbreak. In the 2010s, Chinese scientists traced the virus through the intermediary of Asian palm civets to cave-dwelling horseshoe bats in Xiyang Yi Ethnic Township, Yunnan.

<span class="mw-page-title-main">Influenza vaccine</span> Vaccine against influenza

Influenza vaccines, colloquially known as flu shots or the flu jab, are vaccines that protect against infection by influenza viruses. New versions of the vaccines are developed twice a year, as the influenza virus rapidly changes. While their effectiveness varies from year to year, most provide modest to high protection against influenza. Vaccination against influenza began in the 1930s, with large-scale availability in the United States beginning in 1945.

<span class="mw-page-title-main">Immunization during pregnancy</span>

Immunization during pregnancy is the administration of a vaccine to a pregnant individual. This may be done either to protect the individual from disease or to induce an antibody response, such that the antibodies cross the placenta and provide passive immunity to the infant after birth. In many countries, including the US, Canada, UK, Australia and New Zealand, vaccination against influenza, COVID-19 and whooping cough is routinely offered during pregnancy.

<span class="mw-page-title-main">Social distancing</span> Infection control technique by keeping a distance from each other

In public health, social distancing, also called physical distancing, is a set of non-pharmaceutical interventions or measures intended to prevent the spread of a contagious disease by maintaining a physical distance between people and reducing the number of times people come into close contact with each other. It usually involves keeping a certain distance from others and avoiding gathering together in large groups.

<span class="mw-page-title-main">Airborne transmission</span> Disease transmission by airborne particles

Airborne transmission or aerosol transmission is transmission of an infectious disease through small particles suspended in the air. Infectious diseases capable of airborne transmission include many of considerable importance both in human and veterinary medicine. The relevant infectious agent may be viruses, bacteria, or fungi, and they may be spread through breathing, talking, coughing, sneezing, raising of dust, spraying of liquids, flushing toilets, or any activities which generate aerosol particles or droplets.

<span class="mw-page-title-main">COVID-19</span> Contagious disease caused by SARS-CoV-2

Coronavirus disease 2019 (COVID-19) is a contagious disease caused by the coronavirus SARS-CoV-2. The first known case was identified in Wuhan, China, in December 2019. Most scientists believe the SARS-CoV-2 virus entered into human populations through natural zoonosis, similar to the SARS-CoV-1 and MERS-CoV outbreaks, and consistent with other pandemics in human history. Social and environmental factors including climate change, natural ecosystem destruction and wildlife trade increased the likelihood of such zoonotic spillover. The disease quickly spread worldwide, resulting in the COVID-19 pandemic.

<span class="mw-page-title-main">Bonnie Henry</span> Canadian public health officer

Bonnie J. Fraser Henry is a Canadian epidemiologist, physician, and public servant who has been the provincial health officer at the British Columbia Ministry of Health since 2014. Henry is also a clinical associate professor at the University of British Columbia. She is a specialist in public health and preventive medicine, and is a family doctor. In her role as provincial health officer, Henry notably led the response to COVID-19 in British Columbia (BC).

<span class="mw-page-title-main">Kizzmekia Corbett</span> American immunologist

Kizzmekia "Kizzy" Shanta Corbett is an American viral immunologist. She is an Assistant Professor of Immunology and Infectious Diseases at Harvard T.H. Chan School of Public Health and the Shutzer Assistant Professor at the Harvard Radcliffe Institute since June 2021.

<span class="mw-page-title-main">Arnold Monto</span> American physician and epidemiologist

Arnold Monto is an American physician and epidemiologist. At the University of Michigan School of Public Health, Monto is the Thomas Francis, Jr. Collegiate Professor Emeritus of Public Health, professor emeritus of both epidemiology and global public health, and co-director of the Michigan Center for Respiratory Virus Research & Response. His research focuses on the occurrence, prevention, and treatment of viral respiratory infections in industrialized and developing countries' populations.

Samira Mubareka is a Canadian microbiologist who is a clinical scientist at the Sunnybrook Health Sciences Centre in Toronto, Ontario. Her research considers the influenza virus, viral transmission and aerobiology. During the COVID-19 pandemic Mubareka isolated the genome of Severe acute respiratory syndrome coronavirus 2 in an effort to improve detection and diagnostics. She served as a member of the Ontario COVID-19 Science Advisory Table.

Eleni Nastouli is a Greek clinical virologist who works at University College London Hospitals NHS Foundation Trust (UCLH) and Great Ormond Street Hospital. At UCLH, Nastouli leads the Advanced Pathogen Diagnostics Unit, where she develops technologies for genome sequencing as well as studying how viruses are transmitted around hospitals. During the COVID-19 pandemic Nastouli led an investigation into infection rates amongst healthcare workers.

Helen Y. Chu is an American immunologist who is an assistant professor of medicine at the University of Washington. Her research considers maternal immunization, with a focus on influenza and respiratory syncytial virus. During the COVID-19 pandemic, Chu was the first physician to recognise community transmission of the coronavirus disease within the United States.

Science diplomacy is the collaborative efforts by local and global entities to solve global issues using science and technology as a base. In science diplomacy, collaboration takes place to advance science but science can also be used to facilitate diplomatic relations. This allows even conflicting nations to come together through science to find solutions to global issues. Global organizations, researchers, public health officials, countries, government officials, and clinicians have previously worked together to create effective measures of infection control and subsequent treatment. They continue to do so through sharing of resources, research data, ideas, and by putting into effect laws and regulations that can further advance scientific research. Without the collaborative efforts of such entities, the world would not have the vaccines and treatments we now possess for diseases that were once considered deadly such as tuberculosis, tetanus, polio, influenza, etc. Historically, science diplomacy has proved successful in diseases such as SARS, Ebola, Zika and continues to be relevant during the COVID-19 pandemic today.

<span class="mw-page-title-main">Impact of the COVID-19 pandemic on other health issues</span> Health consequences of outbreak beyond the COVID-19 disease itself

The COVID-19 pandemic has had many impacts on global health beyond those caused by the COVID-19 disease itself. It has led to a reduction in hospital visits for other reasons. There have been 38 per cent fewer hospital visits for heart attack symptoms in the United States and 40 per cent fewer in Spain. The head of cardiology at the University of Arizona said, "My worry is some of these people are dying at home because they're too scared to go to the hospital." There is also concern that people with strokes and appendicitis are not seeking timely treatment. Shortages of medical supplies have impacted people with various conditions.

<span class="mw-page-title-main">Jason McLellan</span> American structural biologist

Jason S. McLellan is a structural biologist, professor in the Department of Molecular Biosciences and Robert A. Welch Chair in Chemistry at The University of Texas at Austin who specializes in understanding the structure and function of viral proteins, including those of coronaviruses. His research focuses on applying structural information to the rational design of vaccines and other therapies for viruses, including SARS-CoV-2, the novel coronavirus that causes COVID-19, and respiratory syncytial virus (RSV). McLellan and his team collaborated with researchers at the National Institute of Allergy and Infectious Diseases’ Vaccine Research Center to design a stabilized version of the SARS-CoV-2 spike protein, which biotechnology company Moderna used as the basis for the vaccine mRNA-1273, the first COVID-19 vaccine candidate to enter phase I clinical trials in the U.S. At least three other vaccines use this modified spike protein: those from Pfizer and BioNTech; Johnson & Johnson and Janssen Pharmaceuticals; and Novavax.

Richard Schabas is a retired public health physician who served as the Chief Medical Officer of Health in Ontario from 1987 to 1997. Schabas also served as the Head of Preventive Oncology at Cancer Care Ontario from 1997 to 2001 and served as chief of staff at York Central Hospital from 2002 to 2005 during the 2002-2004 SARS outbreak. In 2005, he became the public health officer of Hastings, Ontario and Prince Edward, Ontario and remained in this position until his retirement in 2016. In 2021, Schabas criticized the Ontario government's response to the COVID-19 pandemic.

Vaccine-associated enhanced respiratory disease (VAERD), or simply enhanced respiratory disease (ERD), is an adverse event where an exacerbated course of respiratory disease occurs with higher incidence in the vaccinated population than in the control group. It is a barrier against vaccine development that can lead to its failure.

Dr. Shelley Deeks, MD, MHSc, FRCPC, FFAFPM, is a Canadian public health expert who is the chair of the National Advisory Committee on Immunization. Her advertised "specialities include communicable disease control, outbreak investigations, vaccine safety, epidemiology and program evaluation." She is a fellow of the Royal College of Physicians of Canada and the Australian Faculty of Public Health Medicine. Deeks was the executive lead in Ontario's COVID-19 pandemic response in 2020 in her role at Public Health Ontario.

<span class="mw-page-title-main">John R. Mascola</span> American Physician-Scientist

John R. Mascola is an American physician-scientist, immunologist and infectious disease specialist. He was the director of the Vaccine Research Center (VRC), part of the National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). He also served as a principal advisor to Anthony Fauci, director of NIAID, on vaccines and biomedical research affairs. Mascola is the current Chief Scientific Officer for ModeX Therapeutics.

Anna Banerji M.D., O. Ont. is a Toronto infectious disease doctor, tropical disease specialist, pediatrician, public health specialist, academic, and activist. She is the founder and chair of both the North American Refugee Health Conference in Canada and the Indigenous Health Conference, and the co-founder of the Society of Refugee Healthcare Providers. She was awarded the Dr Peter Bryce Henderson for her advocacy for Indigenous children.

References

  1. 1 2 "Pandemic 3.0". University of Toronto Medicine Magazine. Faculty of Medicine. 26 March 2014. Archived from the original on 28 June 2014. Retrieved 8 April 2020.
  2. 1 2 3 4 5 6 7 "Staff Directory: Allison McGeer". eportal.mountsinai.ca. Retrieved 2020-04-06.
  3. ↑ "Allison Mcgeer | Institute of Health Policy, Management and Evaluation". ihpme.utoronto.ca. Archived from the original on 2016-08-21. Retrieved 2020-04-06.
  4. ↑ "| Laboratory Medicine and Pathobiology --- University of Toronto". www.lmp.utoronto.ca. Archived from the original on 2020-04-06. Retrieved 2020-04-06.
  5. ↑ "Dr. Allison McGeer answers common questions about the flu and the flu shot". Sinai Health. 2018-10-17. Retrieved 2020-04-06.
  6. ↑ Andrew, Melissa K.; McElhaney, Janet E.; McGeer, Allison A.; Hatchette, Todd F.; Leblanc, Jason; Webster, Duncan; Bowie, William; Poirier, Andre; Nichols, Michaela K.; McNeil, Shelly A.; Investigators, on behalf of the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance Network (2020-03-09). "Influenza surveillance case definitions miss a substantial proportion of older adults hospitalized with laboratory-confirmed influenza: A report from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS) Network". Infection Control & Hospital Epidemiology. 41 (5): 499–504. doi:10.1017/ice.2020.22. ISSN   0899-823X. PMID   32146920. S2CID   212639677.
  7. ↑ "Coronavirus Q and A: We asked experts to answer some of your most pressing questions. Here's what they had to say". thestar.com. 2020-01-27. Retrieved 2020-04-06.
  8. ↑ Chung, Hannah; Buchan, Sarah A; Campigotto, Aaron; Campitelli, Michael A; Crowcroft, Natasha S; Dubey, Vinita; Gubbay, Jonathan B; Karnauchow, Timothy; Katz, Kevin; McGeer, Allison J; McNally, J Dayre (2021-09-01). "Influenza Vaccine Effectiveness Against All-Cause Mortality Following Laboratory-Confirmed Influenza in Older Adults, 2010–2011 to 2015–2016 Seasons in Ontario, Canada". Clinical Infectious Diseases. 73 (5): e1191–e1199. doi:10.1093/cid/ciaa1862. ISSN   1058-4838. PMC   8423473 . PMID   33354709.
  9. ↑ Abe, Kento T.; Hu, Queenie; Mozafarihashjin, Mohammad; Samson, Reuben; Manguiat, Kathy; Robinson, Alyssia; Rathod, Bhavisha; Hardy, W. Rod; Wang, Jenny H.; Iskilova, Mariam; Pasculescu, Adrian (2021-08-27). "Neutralizing antibody responses to SARS-CoV-2 variants in vaccinated Ontario long-term care home residents and workers". medRxiv   10.1101/2021.08.06.21261721v2 .
  10. ↑ Yau, Kevin; Abe, Kento T.; Naimark, David; Oliver, Matthew J.; Perl, Jeffrey; Leis, Jerome A.; Bolotin, Shelly; Tran, Vanessa; Mullin, Sarah I.; Shadowitz, Ellen; Gonzalez, Anny (2021-09-02). "Evaluation of the SARS-CoV-2 Antibody Response to the BNT162b2 Vaccine in Patients Undergoing Hemodialysis". JAMA Network Open. 4 (9): e2123622. doi:10.1001/jamanetworkopen.2021.23622. ISSN   2574-3805. PMC   8414193 . PMID   34473256.
  11. ↑ "New Sars warning in Toronto". The Guardian. Reuters. 2003-05-27. ISSN   0261-3077 . Retrieved 2020-04-06.
  12. ↑ "Canadian scientist remains cautious of new coronavirus: 'It is very reminiscent of SARS'". ottawacitizen.com. Retrieved 2020-04-06.
  13. ↑ Krauss, Clifford (2003-04-24). "The Sars Epidemic: The Overview; Travelers Urged to Avoid Toronto Because of Sars". The New York Times. ISSN   0362-4331 . Retrieved 2020-04-06.
  14. ↑ McGeer, Allison (2004-07-15). "Let Him Who Desires Peace Prepare for War: United States Hospitals and Severe Acute Respiratory Syndrome Preparedness". Clinical Infectious Diseases. 39 (2): 275–277. doi: 10.1086/421784 . ISSN   1058-4838. PMC   7107923 . PMID   15307039.
  15. ↑ Mackay, Brad (2003-05-13). "SARS: "a domino effect through entire system"". CMAJ. 168 (10): 1308–1308–a. ISSN   0820-3946. PMC   154202 . PMID   12743085.
  16. ↑ "A specialist on front line forced to fight her own battle against SARS" . Retrieved 2020-04-06.
  17. 1 2 Poutanen, Susan M.; McGeer, Allison J. (2004). "Transmission and Control of SARS". Current Infectious Disease Reports. 6 (3): 220–227. doi:10.1007/s11908-004-0012-7. ISSN   1523-3847. PMC   7089465 . PMID   15142486.
  18. ↑ Raboud, Janet; Shigayeva, Altynay; McGeer, Allison; Bontovics, Erika; Chapman, Martin; Gravel, Denise; Henry, Bonnie; Lapinsky, Stephen; Loeb, Mark; McDonald, L. Clifford; Ofner, Marianna (2010-05-19). "Risk Factors for SARS Transmission from Patients Requiring Intubation: A Multicentre Investigation in Toronto, Canada". PLOS ONE. 5 (5): e10717. Bibcode:2010PLoSO...510717R. doi: 10.1371/journal.pone.0010717 . ISSN   1932-6203. PMC   2873403 . PMID   20502660.
  19. ↑ "WORLD: How doctors trace an outbreak". ThoroldNews.com. 12 February 2020. Retrieved 2020-04-06.
  20. ↑ Loeb, Mark; McGeer, Allison; Henry, Bonnie; Ofner, Marianna; Rose, David; Hlywka, Tammy; Levie, Joanne; McQueen, Jane; Smith, Stephanie; Moss, Lorraine; Smith, Andrew (2004). "SARS among Critical Care Nurses, Toronto". Emerging Infectious Diseases. 10 (2): 251–255. doi:10.3201/eid1002.030838. ISSN   1080-6040. PMC   3322898 . PMID   15030692.
  21. 1 2 "The mysteries of microbiology: Q&A with Professor Allison McGeer | Laboratory Medicine and Pathobiology --- University of Toronto". www.lmp.utoronto.ca. Archived from the original on 2020-04-06. Retrieved 2020-04-06.
  22. ↑ Branswell, Helen (2013-06-04). "WHO expert team, including Canadian, in Saudi investigating MERS outbreak". CTVNews. Retrieved 2020-04-06.
  23. ↑ "Middle East Respiratory Syndrome (MERS) virus investigation". ScienceDaily. Retrieved 2020-04-06.
  24. ↑ "Can you have coronavirus and not feel sick? A doctor answers your COVID-19 questions". CBC. 2020-03-18. Retrieved 2020-04-06.
  25. 1 2 Nanowski, Natalie (2020-03-12). "The COVID-19 pandemic: What it is, who's at risk, and how you can protect yourself" . Retrieved 2020-04-06.
  26. ↑ "The 2019 coronavirus is not like SARS - Dr. Allison McGeer". Mayjorad Pharmacies. Archived from the original on 2020-04-06. Retrieved 2020-04-06.
  27. 1 2 "About Us". Ontario COVID-19 Science Advisory Table. Retrieved 2022-03-17.
  28. 1 2 "COVID-19 Expert Panel". Government of Canada. 2021-01-14. Archived from the original on 2021-11-29. Retrieved 2022-03-17.
  29. ↑ "U of T infectious disease expert Allison McGeer on coronavirus risks – and uncertainties". University of Toronto News. Retrieved 2020-04-06.
  30. ↑ Branswell,STAT, Helen. "Experts Warn of Possible Sustained Global Spread of New Coronavirus". Scientific American. Retrieved 2020-04-06.
  31. ↑ "Containing new coronavirus may not be feasible, experts say". STAT. 2020-01-26. Retrieved 2020-04-06.
  32. 1 2 Miller, Adam. "'The time is now to act': COVID-19 spreading in Canada with no known link to travel, previous cases". CBC News. Retrieved 2020-04-06.
  33. ↑ Ireland, Nicole. "COVID-19: The latest guidance for Canadians on travel, quarantines and what to do if you have symptoms". 2020-03-12. Retrieved 2020-04-06.
  34. 1 2 3 4 5 "Scientists look for signs of air transmission of COVID-19". The Globe and Mail Inc. 2 April 2020. Retrieved 2020-04-06.
  35. ↑ "The coronavirus question: To mask or not to mask". Macleans. Retrieved 2020-04-06.
  36. ↑ Bégin, Philippe; Callum, Jeannie; Jamula, Erin; Cook, Richard; Heddle, Nancy M.; Tinmouth, Alan; Zeller, Michelle P.; Beaudoin-Bussières, Guillaume; Amorim, Luiz; Bazin, Renée; Loftsgard, Kent Cadogan (2021). "Convalescent plasma for hospitalized patients with COVID-19: an open-label, randomized controlled trial". Nature Medicine. 27 (11): 2012–2024. doi:10.1038/s41591-021-01488-2. ISSN   1078-8956. PMC   8604729 . PMID   34504336.
  37. ↑ Canadian Institutes of Health Research (9 September 2010). "Assessing the Association Between Frailty and Outcome of COVID-19 Infection". Canadian Research Information System. Archived from the original on 2022-03-26. Retrieved 2022-03-26.
  38. ↑ Semeniuk, Ivan (2021-05-08). "Once a little-known health body, NACI finds itself in the pandemic spotlight over COVID-19 vaccine debate". The Globe and Mail. Retrieved 2022-03-17.
  39. ↑ Ireland, Nicole (2021-09-29). "COVID-19 vaccine boosters recommended for long-term care residents, national advisory committee says". CBC News. Retrieved 2022-03-17.
  40. 1 2 3 "Ontario Immunization Advisory Committee (OIAC)". Public Health Ontario. Archived from the original on 2021-11-10. Retrieved 2022-03-17.
  41. ↑ "Expert Advisory Group on Antimicrobial Resistance (EAGAR) - Membership". Public Health Agency of Canada. 2021-06-11. Archived from the original on 2022-01-27. Retrieved 2022-03-17.
  42. ↑ "Partners – Page 11". National Collaborating Centre for Infectious Diseases. Archived from the original on 2022-01-16. Retrieved 2022-03-17.
  43. ↑ "Toronto's 30 Best Doctors". Toronto Life. 2014-03-05. Retrieved 2020-04-06.
  44. ↑ "May Cohen Award for Women Mentors". Canadian Medical Association. 2015.
  45. ↑ "AMMI Canada Lifetime Achievement Award". Association of Medical Microbiology and Infectious Disease Canada. 2016.
  46. ↑ "Norman Rosenblum Award for Excellence in Mentorship in the MD/PhD Program". University of Toronto MD Program. 2021.
  47. ↑ "2021 Annual Conference Final Program" (PDF). AMMI Canada - CACMID. 2021-04-25. Retrieved 2022-03-17.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.